Comparative Pharmacology
Head-to-head clinical analysis: LARIN 1 20 versus LARIN FE 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN 1 20 versus LARIN FE 1 5 30.
LARIN 1/20 vs LARIN FE 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity, inhibiting sperm penetration; alters endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration; alters endometrial receptivity. Norethindrone also decreases ovarian estrogen production.
One tablet (0.1 mg levonorgestrel/20 mcg ethinyl estradiol) orally once daily for 21 days followed by 7 placebo days.
One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets.
None Documented
None Documented
Norethindrone: 7.6 hours (range 5-14); Ethinyl estradiol: 13.2 hours (range 8-20). Clinical context: Steady-state achieved within 5-10 days.
Ethinyl estradiol terminal half-life is approximately 13-17 hours; norethindrone terminal half-life is approximately 7-10 hours. Steady-state is reached within 5-10 days.
Approximately 60% renal (30% norethindrone, 30% ethinyl estradiol metabolites) and 40% fecal (biliary excretion of conjugates).
Ethinyl estradiol and norethindrone are primarily excreted via renal (urine) and fecal routes. Approximately 40-50% of ethinyl estradiol is excreted renally as metabolites, with 20-30% in feces. Norethindrone metabolites are excreted ~50-70% renally and 20-30% fecally. Less than 5% is excreted unchanged.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive